Marker Therapeutics, Inc. (NASDAQ:MRKR) Sees Large Growth in Short Interest

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 232,100 shares, an increase of 20.0% from the January 15th total of 193,400 shares. Currently, 3.0% of the company’s shares are sold short. Based on an average daily trading volume, of 72,900 shares, the short-interest ratio is presently 3.2 days.

Insider Transactions at Marker Therapeutics

In other news, Director Steve Elms purchased 11,085 shares of Marker Therapeutics stock in a transaction dated Monday, December 23rd. The shares were bought at an average cost of $3.20 per share, with a total value of $35,472.00. Following the completion of the transaction, the director now directly owns 325,370 shares in the company, valued at $1,041,184. This trade represents a 3.53 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the transaction, the insider now owns 1,625,678 shares in the company, valued at $5,202,169.60. This represents a 51.73 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 14.50% of the company’s stock.

Hedge Funds Weigh In On Marker Therapeutics

A number of large investors have recently modified their holdings of MRKR. Invst LLC bought a new stake in Marker Therapeutics during the third quarter worth about $56,000. Northern Trust Corp increased its position in shares of Marker Therapeutics by 66.9% during the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after purchasing an additional 21,703 shares during the last quarter. LPL Financial LLC bought a new stake in shares of Marker Therapeutics during the 4th quarter worth approximately $248,000. Aisling Capital Management LP boosted its holdings in shares of Marker Therapeutics by 3.5% in the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after buying an additional 11,084 shares during the last quarter. Finally, Blue Owl Capital Holdings LP bought a new position in shares of Marker Therapeutics in the fourth quarter valued at $1,724,000. 22.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on MRKR. LADENBURG THALM/SH SH increased their target price on Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Brookline Capital Management upgraded Marker Therapeutics to a “strong-buy” rating in a report on Monday, February 10th.

Marker Therapeutics Price Performance

Shares of NASDAQ MRKR traded up $0.02 during midday trading on Friday, reaching $1.72. The company’s stock had a trading volume of 61,990 shares, compared to its average volume of 78,471. The stock has a 50 day simple moving average of $2.81 and a 200-day simple moving average of $3.20. Marker Therapeutics has a fifty-two week low of $1.48 and a fifty-two week high of $5.99.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.